On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- The story of multiple sclerosis: 1838-1993
- The symptoms of multiple sclerosis
- Pathogenesis of MS
- Pathogenesis of MS: possible therapies
- Pathological hetrogeneity in MS
- Impairment of function and the MS clinical course
- Reduced MS activity with interferon-beta-1b
- Pivotal trials in relapsing-remitting MS (1)
- Pivotal trials in relapsing-remitting MS (2)
- Cochrane analysis of interferon efficacy
- Monoclonal antibody trialed in MS
- Pivotal trials of ZENAPAX (daclizumab): results
- Nataluzimab\tysabru reduces relapse rate
- Pivotal trials of tysabri - 2 year results
- PML with tysbari
- The story of Campath-1H treatment
- Campath-1H causes prolonged T-cell depletion
- Effects of the first dose of Campath-1H
- Axonal damage is caused before conduction block
- Campath-1H suppresses relapses in MS
- Effect of Campath-1H on disability
- Comparison of trials on Campath-1H and tysbari
- Infections after Campath-1H
- Graves' disease after Campath-1H treatment ( 1)
- Graves' disease after Campath-1H treatment (2)
- Immune trombocytopenia after Campath-1H
- Autoimmune disease after Campath-1H
- Other examples of reconstitution autoimmunity
- Pathology and course of MS
- Treatment of MS - 2006 and beyond
Topics Covered
- The story of multiple sclerosis
- Symptoms
- Pathogenesis
- Pathological heterogeneity
- Axonal degeneration
- Current treatments
- Interferons and glatiramer
- Monoclonal antibody treatment of multiple sclerosis
- Daclizumab
- Natalizumab
- The story of Campath-1H
- The effect of Campath-1H on disability depends upon the stage of the disease
- Graves' disease
- Immune thrombocytopenia
- Future treatment of multiple sclerosis
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Coles, A. and Compston, A. (2007, October 1). Antibody therapy of multiple sclerosis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/KLCK1482.Export Citation (RIS)
Publication History
- Published on October 1, 2007
Financial Disclosures
- Dr. Alasdair Coles has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
- Prof. Alastair Compston has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.